此前，蔡司光学、中山大学中山眼科中心、广州图书馆已共建"健康阅读推广实践基地"，打造 "EYE 护 视界 阅见未来" 爱眼系列活动，收获广泛认可。今年活动升级，广东省近视防控专家宣讲团专业力量加 持，不仅有专家讲座普及眼健康知识，蔡司也将专业视力检查服务送到家长和孩子身边。现场还通过游 戏挑战与互动打卡等方式，让参与者在轻松氛围中沉浸式学习护眼知识。 在数字化生活日益普及的今天，长时间使用电子屏幕、不当的阅读姿势与习惯，正持续加剧居民尤其是 青少年的视觉健康风险。针对这一现状，广州图书馆第一党支部书记、儿童与青少年部主任冯莉表示， 良好的阅读习惯和视力健康相辅相成，广州图书馆长期为不同年龄段的未成年人开展内容丰富的阅读活 动，希望孩子们能够保持对阅读的热爱，在获取知识的同时保护好眼睛。 "眼睛检查有什么用？""近视是不是长大做个手术就好了？""不同眼镜片有什么区别"……9月14日，广 州图书馆负一层大厅化身为眼健康科普专场，数百名家长与孩子穿梭于各个体验区，这些日常生活中常 见的疑问，在"EYE护视界 阅见未来"蔡司眼健康中国行公益活动的现场得到了专业而亲切的解答。 在迎来首个"全国科普月"及"第十一个全国近 ...

Group 1 - The article highlights the rising costs and pressures faced by parents regarding their children's health, particularly in managing myopia, dental issues, and height concerns [2][57] - A significant market has emerged around myopia treatment, with the overall myopia rate among children and adolescents in China reaching 52.7%, indicating that one in two children is affected [27][28] - Companies in the myopia treatment sector, such as Opcon Vision and Aier Eye Hospital, are experiencing substantial revenue growth, with Opcon Vision's revenue reaching 1.814 billion and Aier Eye Hospital's revenue at 20.983 billion [30][31] Group 2 - The orthodontics market is also booming, with companies like Times Angel and Invisalign dominating the space, capturing significant market shares and generating substantial revenues [43][44] - The article discusses the high costs associated with dental treatments, with some families spending up to 60,000 on orthodontic solutions, reflecting a growing trend in dental care for children [34][36] - The prevalence of dental issues among children is alarming, with a reported 67.82% incidence of malocclusion, leading to increased demand for orthodontic services [41] Group 3 - Height management is emerging as a new area of concern for parents, with the market for growth hormone treatments and related products projected to reach 8-12 billion, growing at a compound annual growth rate of over 25% [56][57] - Companies like Jinsai Pharmaceutical are leading the growth in the height management sector, with a reported revenue of 10.67 billion, indicating a strong market presence [56] - The societal pressures regarding height are reflected in the increasing willingness of parents to invest heavily in treatments, with some spending tens of thousands on growth hormone therapies [48][49]

Core Viewpoint - The acquisition of 75% equity in Shanyang Qicheng Hospital Management Co., Ltd. for 334 million yuan by Opcon Vision reflects the company's need for business transformation and new growth opportunities amid declining performance in its core OK lens market [1][2]. Financial Performance - In 2024, Opcon Vision reported revenue of 1.814 billion yuan, a year-on-year increase of 4.4%, while net profit attributable to shareholders was 572 million yuan, down 14.16% [1]. - For Q1 2025, the company achieved revenue of 478 million yuan, a 2.95% increase year-on-year, but net profit fell by 16.93% to 160 million yuan [1]. - The sales revenue from hard contact lenses, primarily OK lenses, was 760 million yuan in 2024, representing a decline of 6.73% [1][9]. Strategic Acquisition - The acquisition of Shanyang Qicheng, established in May 2024, is seen as a strategic move to extend into the downstream medical services sector, aiming to create a complete industry chain from products to services [2][3]. - The assessed value of Shanyang Qicheng's equity is 454 million yuan, with a significant appreciation of 771.49% over its book net assets [3]. Funding and Investment Concerns - The acquisition funding of 334 million yuan primarily comes from the company's 2022 private placement, originally intended for community eye care service terminal construction, which has seen only 10% of the planned investment completed by the end of 2024 [4]. - The slow progress of the original project raises concerns about the efficiency of fund utilization [4]. Market Position and Strategy - The acquisition is expected to help Opcon Vision consolidate and expand its market share in the Southwest region, reducing reliance on the highly competitive East China market [5]. - The business structure of Shanyang Qicheng includes approximately 40% of refractive surgery and 14% related to OK lenses, aligning well with Opcon Vision's existing product line [5][10]. Performance Guarantees - The acquisition includes a 10-year performance commitment, with net profit targets set for 2025-2029, requiring significant growth compared to 2024's net profit of 30.58 million yuan [6]. - The long-term performance commitments reflect the company's high expectations for the acquisition while implementing strict risk control measures [6]. Industry Trends - The youth myopia prevention market in China is undergoing significant changes, with a reported overall myopia rate of 52.7% among children and adolescents [7]. - The competitive landscape for OK lenses has intensified, with over 20 registered products leading to price competition and a shift towards alternative solutions like defocus glasses [9][10]. Long-term Outlook - The demand for professional vision health services is expected to grow, driven by the "Healthy China" strategy and increasing health awareness among parents [11].

Group 1 - The core viewpoint emphasizes the importance of controlling the progression of myopia in children rather than attempting to reverse it, as most optical methods can only slow down the increase in myopia [2][3] - For children around the age of 10 with myopia under 100 degrees, optical methods like functional frame glasses and OK lenses may show some cases of myopia regression, but this is not common [2] - It is crucial to conduct cycloplegic refraction tests to accurately assess myopia, as traditional vision tests may not detect low degrees of myopia in children who still have normal visual acuity [3] Group 2 - For children who have already developed myopia, intervention measures should be tailored based on the degree of myopia and astigmatism, as well as the individual child's situation [3] - Functional frame glasses or OK lenses are recommended for children with relatively low myopia and high astigmatism, but adjustments should be made based on the child's response and axial growth [3] - Children with low myopia or pure astigmatism may be better suited to wear frame glasses [3]

Core Viewpoint - Myopia among adolescents has become a global public health issue, with over 50% prevalence in China, necessitating new intervention methods beyond existing treatments like low-concentration atropine eye drops [1][2]. Group 1: Current Challenges in Myopia Prevention - Low-concentration atropine effectively delays myopia progression by approximately 60% but only controls axial length growth by about 30%, indicating a significant limitation [2]. - The dual effects of atropine include measurement bias due to its dilation effect and a compensatory response that may lead to pathological elongation of the eyeball [2]. Group 2: Discovery of Crocetin - A groundbreaking study from Japan identified Crocetin as a potent activator of EGR-1, a key transcription factor in regulating cell proliferation and differentiation, which may intervene in myopia progression [3]. - In a mouse model, Crocetin significantly reduced axial length growth compared to the control group [5]. Group 3: Clinical Trials and Efficacy - A clinical study involving 67 children aged 6-12 showed that daily oral administration of 7.5mg Crocetin for six months resulted in a significant increase in choroidal thickness compared to the control group [8][10]. - The increase in choroidal thickness is crucial as it improves retinal metabolic conditions and inhibits scleral hypoxic expansion [10]. Group 4: Mechanisms of Action - Crocetin's effects may be attributed to multiple pathways, including EGR-1 activation, antioxidant stress response, and improved choroidal blood flow [11][13]. - Both spherical equivalent refraction and axial length measurements showed significant improvement in the Crocetin group compared to controls [12]. Group 5: Advantages and Future Prospects - Crocetin offers several advantages over traditional drugs, including its natural origin, safety for long-term use, and multi-target action addressing both axial length and refractive error [14]. - Ongoing multi-center clinical trials in China aim to validate the efficacy of different doses of Crocetin for children, with potential complementary use alongside low-concentration atropine [14]. - The development of precise drug delivery systems, such as nano-sustained release eye drops, may position Crocetin as a key player in altering the course of myopia [15].

Core Viewpoint - The leading ophthalmic drug company, Xingqi Eye Medicine, reported significant growth in its 2024 financial results, driven primarily by the successful launch of its myopia treatment, atropine sulfate eye drops, which has become a key growth engine for the company [1][4]. Financial Performance - In 2024, the company achieved a total revenue of 1.943 billion yuan, marking a year-on-year increase of 32.42% [2]. - The net profit attributable to shareholders reached 338 million yuan, reflecting a growth of 40.84% [2]. - The net profit after deducting non-recurring gains and losses was 347 million yuan, with a growth rate of 44.54% [2]. - The gross profit margin improved to 78.33%, an increase of 0.96 percentage points compared to the previous year [6]. Product Performance - The "myopia miracle drug," atropine sulfate eye drops (marketed as "Mei Ou Pin"), saw its revenue in the eye drop segment surge by 106.08% year-on-year following its approval for use in children aged 6-12 [4][6]. - The company has a diverse product line with 60 approved ophthalmic drug products, of which 38 are included in the medical insurance directory [6]. Market Competition - The market is becoming increasingly competitive, with rivals such as Hengrui Medicine and Zhaoke Ophthalmology nearing the launch of similar products, which could impact Xingqi's market share [3][8]. - Alternative solutions like orthokeratology lenses are also diverting patients, creating a dual challenge for the company [9]. - The company is responding to competition by enhancing its R&D and channel strategies, including advancing clinical trials for different concentrations of atropine eye drops [9]. Strategic Initiatives - The company plans to build a comprehensive service ecosystem to address the competitive landscape in the 300 billion yuan youth myopia prevention market, moving from a single product focus to a platform-based development approach [9].